早期乳腺癌辅助化疗中PICC与输液港安全性随机II期试验
该单中心II期随机试验纳入256例早期乳腺癌辅助化疗患者,比较外周置入中心静脉导管(PICC)与植入式输液港(PORT)的安全性。主要目标为装置植入后35周内导管相关严重不良事件(CR-SAE)发生概率,结果显示PORT组CR-SAE概率为7.8%,PICC组为16.6%(HR=2.2,P=0.036),PICC组不适感更明显,PORT应优先用于辅助化疗给药。
要点
- PORT组35周内CR-SAE概率7.8%,PICC组16.6%,PICC风险显著更高。
- PICC组患者报告的不适感显著多于PORT组。
- 早期乳腺癌辅助化疗应优先选择PORT给药。
核心结论
- 在早期乳腺癌辅助化疗患者中,PICC相比PORT与显著更高的导管相关严重不良事件风险和更多不适相关,PORT应优先用于辅助化疗给药。
研究设计与样本
- 单中心II期随机试验(NCT02095743),纳入适合辅助化疗的早期乳腺癌患者,排除接受治愈性抗凝治疗者,共256例纳入、253例(99%)分析。
主要发现
- 总体31例(12.2%)发生CR-SAE,主要为血栓栓塞事件。
- 意向治疗分析中,PORT组CR-SAE发生概率为7.8%(10次事件),PICC组为16.6%(21次事件),HR=2.2(95%CI 1.03-4.62),P=0.036。
- 符合方案分析中,PICC同样与更高CR-SAE风险相关(HR=2.82,95%CI 1.26-6.25,P=0.007)。
- 两组生活质量无差异,但PICC组报告的不适感显著更多(植入后P=0.002,治疗中期或结束时P<0.001)。
临床怎么用
- 对于接受辅助化疗的早期乳腺癌患者,应优先选择植入式输液港(PORT)而非PICC,以降低导管相关严重不良事件风险并减少患者不适。
局限性
- 本研究为单中心II期随机试验,样本量有限,结论需更大规模多中心试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Both peripherally inserted central catheters (PICCs) and implanted port catheters (PORTs) are used for adjuvant chemotherapy (ACT) administration in patients with early breast cancer (EBC). We aimed to compare the safety between PICCs and PORTs in this setting. PATIENTS AND METHODS: This monocentric phase II randomised trial (NCT02095743) included patients with EBC who were eligible for ACT. Patients with curative anticoagulation therapy were excluded. The primary objective was to identify which device has a lower probability of catheter-related significant adverse events (CR-SAEs) within the 35 weeks after device implantation. The secondary objective was to evaluate quality of life (QoL) and patient satisfaction. RESULTS: From February 2014 to May 2018, 256 patients were included, and 253 (99%) were analysed. Overall, 31 patients (12.2%) experienced CR-SAEs, which mainly included thromboembolic events. In an intention-to-treat analysis, the probability that a CR-SAE would occur was 7.8% (10 events) with PORTs versus 16.6% (21 events) with PICCs (hazard ratio [HR] = 2.2 [1.03-4.62], P = 0.036). In a per-protocol analysis, PICCs were also associated with a higher risk of CR-SAEs than PORTs (HR = 2.82 [1.26-6.25], P = 0.007). Regarding the secondary objectives, if there was no difference in QoL between the arms, then significantly more discomfort was reported among patients with PICCs than among patients with PORTs (P = 0.002 after implantation and P < 0.001 at mid-treatment or at the end of treatment). CONCLUSIONS: CR-SAEs in patients with EBC are frequent but rarely impact the ACT process. Compared with PORTs, PICCs are associated with a significantly higher risk of CR-SAEs and more discomfort. PORTs should be preferred for ACT administration in patients with EBC.
引用
- Clatot F, Fontanilles M, Lefebvre L, et al. Randomised phase II trial evaluating the safety of peripherally inserted catheters versus implanted port catheters during adjuvant chemotherapy in patients with early breast cancer. Eur J Cancer. 2020. PMID: 31931269. doi:10.1016/j.ejca.2019.11.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。